New blood sugar–lowering drugs for type 2 diabetes: a summary of research
Updated
Abstract
GLP-1 analogues achieved a mean HbA1c reduction of 1%, comparable to insulin therapy.
- DPP-4 inhibitors sitagliptin and vildagliptin resulted in mean HbA1c reductions of 0.7% and 0.6%, respectively.
- GLP-1 analogues were associated with gastrointestinal complaints in a large number of patients.
- Sitagliptin was linked to a slight increase in upper respiratory tract infections.
- DPP-4 inhibitors were associated with small weight gain, while patients treated with GLP-1 analogues experienced weight loss.
- Data on long-term efficacy and safety, including complications and mortality, are not yet available.
Simplified